Mace wins the 1st phase of Stevenage Bioscience Catalyst

  • Published on 4th October 2010

Mace wins the 1st phase of Stevenage Bioscience Catalyst

Mace has been appointed to work on the £38m first phase of the Stevenage Bioscience Catalyst development, which is to be located on the GlaxoSmithKline research site. The contracting team has been tasked with finding solutions for the design and procurement processes.

Stevenage Bioscience Catalyst is a joint venture funded by the Department of Business Innovation and Skills, GSK, the Wellcome Trust, the East of England Development Agency and the Technology Strategy Board. The project comprises two buildings designed by FDG Fairhurst which form the first phase of plans for a larger bioscience campus development. The "research hotels" will constitute an incubator and accelerator building in which research scientists can collaborate with colleagues from industry to develop new pharmaceutical products.

Enabling works are due to start in November 2010 with main sub-structure works beginning in January 2011. The first phase of the campus is aiming to be operational by the first quarter of 2012. 

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.